CSL has again ranked among the world’s most valuable companies on the Forbes Global 2000, a list that measures companies on sales, profits, assets and market value.
Since last year, CSL jumped 80 spots in the rankings to 467. Traded on the Australian Securities Exchange, the multinational company today has 32,000 employees and includes business units CSL Behring, which makes medicines for people who have rare and serious diseases; CSL Seqirus, which develops and manufactures vaccines; and the recently acquired CSL Vifor, a leader in iron deficiency and nephrology (kidney care).
CSL also operates CSL Plasma, one of the largest collectors of donated human plasma used to make medicines for diseases such as hemophilia and primary immune deficiency.
Forbes uses data from FactSet Research systems to compile the list, which this year marks its 20th anniversary. Topping the Global 2000 was banking giant JPMorgan with $3.7 trillion in assets. For CSL, the rankings reported $11.7 billion in sales, a $2.17 billion profit; more than $35 billion in assets and a market value of nearly $98 billion.
Earlier this year, CSL was named to another Forbes list: America’s Best Large Employers.